Cancers (May 2022)

DJ-1 Expression Might Serve as a Biologic Marker in Patients with Bladder Cancer

  • Shuhei Hirano,
  • Kazumasa Matsumoto,
  • Kei Tanaka,
  • Noriyuki Amano,
  • Dai Koguchi,
  • Masaomi Ikeda,
  • Yuriko Shimizu,
  • Benio Tsuchiya,
  • Ryo Nagashio,
  • Yuichi Sato,
  • Masatsugu Iwamura

DOI
https://doi.org/10.3390/cancers14102535
Journal volume & issue
Vol. 14, no. 10
p. 2535

Abstract

Read online

The overexpression of DJ-1 protein and its secretion into the bloodstream has been reported in various neoplasms. However, serum levels and the subcellular localization of DJ-1 have not been analyzed in detail in bladder cancer (BC). Our comprehensive analysis of these variables started with the measurement of DJ-1 in serum from 172 patients with BC, 20 patients with urolithiasis and 100 healthy participants. Next, an immunohistochemical study of DJ-1 expression and localization was conducted in 92 patients with BC, and associations with clinicopathologic factors and patient outcomes were evaluated. Serum DJ-1 was significantly higher in patients with BC than in those with urolithiasis or in healthy participants. Immunohistochemically, a cytoplasm-positive (Cy+) and nucleus-negative (N−) DJ-1 pattern was associated with age and pathologic stage. Log-rank tests indicated that the Cy+, N− pattern was significantly associated with overall survival (OS), recurrence-free survival (RFS), and cancer specific survival (CSS). In addition, the Cy+, N− pattern was an independent prognostic factor in the multivariate analysis adjusted for the effects of the clinicopathologic outcomes. The investigation of DJ-1 expression might help physicians to make decisions regarding further follow-up and additional treatments.

Keywords